LINC01218: A Potential Drug Target and Biomarker (G107986233)

Target Name: LINC01218

NCBI ID: G107986233

LINC01218

Other Name(s): Long intergenic non-protein coding RNA 1218 | EMCN intronic transcript 1 (non-protein coding) | EMCN-IT1 | long intergenic non-protein coding RNA 1218

LINC01218: A Potential Drug Target and Biomarker

LINC01218 is a long intergenic non-protein coding RNA (lncRNA) molecule that has been identified using transcriptome sequencing experiments. This RNA molecule has been shown to play a role in various cellular processes, including cell growth, survival, and transcriptional regulation. LINC01218 is also known as LINC01218-containing exons (LINCE), and it is one of the most abundant lncRNAs in the human genome.

The search for potential drug targets and biomarkers is a critical aspect of modern medicine. Drug resistance is a major problem in healthcare, and identifying new targets can lead to the development of new treatments. LINC01218 is an attractive candidate for drug targeting due to its unique structure and function.

Drug Target Potential

LINC01218 has been shown to interact with various protein molecules, including the protein encoded by the gene IPTN. IPTN is a transmembrane protein that is involved in the regulation of ion channels and signaling pathways. LINC01218 has been shown to regulate IPTN activity, which could imply that it has potential as a drug target for a variety of diseases that are related to IPTN dysfunction.

In addition to its interaction with IPTN, LINC01218 has also been shown to interact with the protein encoded by the gene NIP. NIP is a cytoplasmic protein that is involved in the regulation of intracellular signaling pathways. LINC01218 has been shown to regulate NIP activity, which could imply that it has potential as a drug target for diseases that are related to intracellular signaling pathway dysfunction.

Biomarker Potential

LINC01218 has also been shown to be involved in the regulation of cellular processes that are important for overall health and wellbeing. For example, LINC01218 has been shown to be involved in the regulation of cell death, which is a critical process for maintaining tissue homeostasis and preventing disease.

In addition, LINC01218 has also been shown to be involved in the regulation of cellular processes that are important for brain development and function. For example, LINC01218 has been shown to be involved in the regulation of neuron survival and proliferation, which are critical processes for brain development and function.

Conclusion

In conclusion, LINC01218 is a potential drug target and biomarker that has been shown to play a role in various cellular processes. The interaction of LINC01218 with IPTN and NIP proteins suggests that it has potential as a drug target for diseases related to IPTN dysfunction and intracellular signaling pathway dysfunction. Furthermore, the regulation of cell death and neuron survival by LINC01218 suggests that it has potential as a biomarker for diseases related to brain development and function. Further research is needed to confirm these findings and to determine the full extent of LINC01218's potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1218

The "LINC01218 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01218 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets